Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.

Aurelia A Haller; Georg M Lauer; Thomas H King; Charles Kemmler; Valerie Fiolkoski; Yingnian Lu; Don Bellgrau; Timothy C Rodell; David Apelian; Alex Franzusoff

doi:10.1016/j.vaccine.2006.10.035

Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.

Identifier:nobleid.org/w1/20260515/C01AAB5D

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C01AAB5D.svg?ark=w1%2F20260515%2FC01AAB5D)](https://nobleid.org/work/w1/20260515/C01AAB5D)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins.

Identifier:nobleid.org/w1/20260515/C01AAB5D

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/C01AAB5D.svg?ark=w1%2F20260515%2FC01AAB5D)](https://nobleid.org/work/w1/20260515/C01AAB5D)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work